# IL2RA Gene: Structure, Function, and Clinical Significance


## Key Takeaways

- The IL2RA gene encodes CD25, the alpha chain of the high-affinity IL-2 receptor, crucial for T-cell homeostasis, Treg differentiation, and immune tolerance; its dysregulation is linked to autoimmune diseases, immunodeficiencies, and cancers.
- IL2RA's genomic locus on chromosome 10p15.1 features a complex regulatory landscape, including a large first intron with enhancer elements and a downstream super-enhancer regulated by transcription factors like STAT5 and FOXP3, critical for cell-type-specific expression.
- The IL2RA protein, a type I transmembrane glycoprotein with two sushi domains, binds IL-2 with low affinity, but its assembly with IL2RB and IL2RG forms the high-affinity receptor complex essential for IL-2 signaling via JAK-STAT, PI3K/AKT, and MAPK pathways.
- Loss-of-function germline mutations in IL2RA cause Immunodeficiency 41 (IMD41), a severe condition characterized by autoimmunity and lymphoproliferation, while common intronic polymorphisms are associated with susceptibility to Type 1 Diabetes, Multiple Sclerosis, and Rheumatoid Arthritis.
- IL2RA is a validated therapeutic target, with monoclonal antibodies like basiliximab used in transplant rejection prophylaxis, and its signaling pathway is modulated by JAK inhibitors; engineered IL-2 variants and IL-2/anti-IL-2 antibody complexes are also being explored for therapeutic applications.
- Pathogens like HTLV-1 exploit IL2RA by inducing its expression via the viral Tax protein, contributing to Adult T-cell Leukemia/lymphoma, while genetic variants in IL2RA influence susceptibility to infections such as leprosy and leishmaniasis.

---

## Executive Summary & Key Metadata

The Interleukin-2 Receptor Subunit Alpha (IL2RA) gene encodes CD25, the alpha chain of the high-affinity interleukin-2 (IL-2) receptor complex. This gene is a master regulator of immune tolerance, T-cell homeostasis, and the differentiation of regulatory T cells (Tregs). IL2RA is constitutively expressed on Tregs and is inducibly expressed on activated T cells, making it a critical nexus for both pro-inflammatory and immunosuppressive signaling. Its dysregulation—through genetic polymorphism, epigenetic modification, or somatic mutation—is implicated in a broad spectrum of autoimmune diseases, immunodeficiencies, and malignancies. The gene product is also a validated therapeutic target, with monoclonal antibodies such as daclizumab and basiliximab used clinically to modulate immune responses.

| **Attribute** | **Detail** |
| :--- | :--- |
| **HGNC Symbol** | IL2RA |
| **UniProt Accession** | P01589 |
| **Representative PDB ID** | True (e.g., 2ERJ, 2B5I for the IL-2/IL-2Rα complex) |
| **Chromosomal Locus** | 10p15.1 (GRCh38: chr10:6,010,689-6,062,615) |
| **Primary Molecular Function** | High-affinity interleukin-2 receptor subunit; cytokine receptor activity; signal transduction |
| **Disease & Pathology Associations** | Type 1 Diabetes (T1D), Multiple Sclerosis (MS), Rheumatoid Arthritis (RA), Alopecia Areata, Immunodeficiency 41 (with lymphoproliferation and autoimmunity), various cancers |

## 1. Genomic Locus, Chromosomal Organization & Isoforms

### 1.1 Chromosomal Location and Gene Structure

The IL2RA gene is located on the short arm of chromosome 10 at cytogenetic band 10p15.1. The gene spans approximately 52 kilobases (kb) of genomic DNA on the plus strand. The canonical transcript (NM_000417.2) is composed of 8 exons and 7 introns, producing a mature mRNA of roughly 1.5 kb that translates into a 272-amino-acid precursor protein. The mature protein, after cleavage of the 21-amino-acid signal peptide, is 251 amino acids long.

The genomic architecture of IL2RA is notable for its complex regulatory landscape. The promoter region is TATA-less and GC-rich, containing multiple binding sites for constitutively expressed and inducible transcription factors. The first intron is exceptionally large (~14 kb) and harbors several critical enhancer elements and single-nucleotide polymorphisms (SNPs) associated with autoimmune disease susceptibility [1, 2]. This intronic region is a hotspot for regulatory variation, with SNPs such as rs12722489 and rs2104286 altering transcription factor binding and enhancer activity [1, 2].

### 1.2 Promoter Architecture and Transcription Factor Binding

The IL2RA promoter is a paradigm for inducible gene expression in T lymphocytes. It contains a proximal promoter region that is constitutively bound by a variety of transcription factors, including Elf-1, Ets-1, and GABP. However, high-level transcription requires the cooperative binding of inducible factors, most notably Nuclear Factor of Activated T-cells (NFAT) and Nuclear Factor kappa-B (NF-κB). The promoter also contains a STAT5 response element, which is critical for IL-2-mediated positive feedback regulation of IL2RA expression [1].

The activation of IL2RA transcription is a multi-step process. Upon T-cell receptor (TCR) engagement, calcium flux and protein kinase C (PKC) activation lead to the nuclear translocation of NFAT and NF-κB. These factors bind to their cognate sites within the promoter, recruiting co-activators such as p300/CBP, which possess histone acetyltransferase activity. This acetylation relaxes the chromatin structure, allowing for the recruitment of RNA Polymerase II and the general transcription machinery. The transcription factor Sam68 has been shown to direct NF-κB to the IL2RA promoter, acting as a molecular bridge that facilitates the assembly of the enhanceosome [2]. The physical mechanics of this promoter activation have been studied using atomic force microscopy, revealing that the intrinsic curvature and flexibility of the promoter DNA are critical for the recruitment of the transcriptional machinery [1].

### 1.3 Enhancer Elements and Super-Enhancers

Beyond the proximal promoter, the IL2RA locus is regulated by a complex array of distal enhancer elements. Notably, a large super-enhancer (SE) has been identified downstream of the gene, which is extensively bound by STAT5 in mature T cells [1, 2]. This super-enhancer is not a monolithic entity but rather a collection of individual enhancer elements that function in a cell-type-specific and developmental-stage-specific manner [1, 2].

Spolski et al. demonstrated that the Il2ra super-enhancer contains distinct elements that are differentially required for expression in DN2/DN3 thymocytes, Tregs, and mature activated T cells [2]. For instance, one element is crucial for the constitutive expression seen in Tregs, while another is required for the inducible expression in conventional T cells following IL-2 stimulation. This functional partitioning is achieved through the differential binding of transcription factors such as STAT5, Notch, and FOXP3 [2]. The FOXP3 paralogs FOXP1 and FOXP4 have been shown to stabilize the super-enhancer structure, augmenting Treg fitness and ensuring sustained IL2RA expression [2].

The three-dimensional organization of these enhancers is critical. Using chromatin conformation capture (Hi-C) and related techniques, Li et al. showed that the IL2RA promoter physically interacts with these distal enhancer elements, forming a chromatin loop [1]. This looping brings the enhancer-bound transcription factors into proximity with the promoter, facilitating robust transcriptional activation. The formation of these loops is dynamic and is enhanced upon IL-2 stimulation, correlating with increased STAT5 binding and histone acetylation at the enhancer [1].

### 1.4 Alternative Splicing and Isoforms

While the canonical IL2RA transcript is the most abundant and well-characterized, alternative splicing events have been described. A soluble form of IL-2Rα (sIL-2Rα) is generated through proteolytic cleavage of the membrane-bound receptor by the metalloprotease ADAM17 (TACE). This soluble form lacks the transmembrane and intracellular domains and is released into the extracellular space, where it can bind to IL-2 and act as a cytokine sink, modulating IL-2 bioavailability. Elevated levels of sIL-2Rα are a clinical biomarker for T-cell activation and are observed in various autoimmune diseases, hematological malignancies, and transplant rejection [1, 2].

Additionally, several minor splice variants have been reported in public databases (e.g., Ensembl), though their functional significance is largely unexplored. Some of these variants may encode truncated proteins that could potentially act as dominant-negative inhibitors of the full-length receptor, although this remains speculative.

## 2. 3D Protein Domain Architecture & Structural Biology

### 2.1 Primary Structure and Domain Organization

The IL2RA protein (CD25) is a type I transmembrane glycoprotein. Its domain architecture is distinct from the other IL-2 receptor subunits (IL2RB/β and IL2RG/γc), which belong to the cytokine receptor superfamily. Instead, IL2RA is a member of the complement control protein (CCP) family, also known as the sushi domain family.

The mature protein (251 amino acids) is organized into three principal domains:

1.  **Extracellular Domain (N-terminus):** This is the largest domain, spanning approximately 219 amino acids (residues 22-240). It is composed of two tandem "sushi" domains, each of which is a globular module of about 60-70 amino acids. These domains are stabilized by two intra-domain disulfide bonds each and are characterized by a conserved motif of hydrophobic residues. The two sushi domains are arranged in a "V" shape, forming a deep groove that is the primary binding site for IL-2.
2.  **Transmembrane Domain:** A single-pass hydrophobic alpha-helix (residues 241-263) anchors the protein to the cell membrane. This domain is not involved in signal transduction but is essential for proper membrane localization and the formation of the high-affinity receptor complex.
3.  **Cytoplasmic Domain (C-terminus):** This is a short, proline-rich intracellular tail of approximately 11 amino acids (residues 264-272). Unlike IL2RB and IL2RG, the IL2RA cytoplasmic domain is very short and lacks intrinsic signaling motifs, such as JAK-binding boxes or immunoreceptor tyrosine-based activation motifs (ITAMs). It does not directly participate in intracellular signaling cascades. However, recent research has shown that this domain can interact with other proteins, such as inhibitory phosphatases, to modulate signaling output [2].

### 2.2 The IL-2 Binding Site and Receptor Complex Assembly

The primary function of IL2RA is to capture IL-2 and present it to the signaling subunits IL2RB and IL2RG. The affinity of IL-2 for IL2RA alone is relatively low (Kd ≈ 10 nM). However, the affinity of IL-2 for the heterotrimeric complex (IL2RA/IL2RB/IL2RG) is approximately 10 pM, which is 100-1000 times higher than for the IL2RB/IL2RG dimer alone (Kd ≈ 1 nM). This dramatic increase in affinity is the key functional contribution of IL2RA.

The crystal structure of the quaternary complex (IL-2/IL2RA/IL2RB/IL2RG) has been solved, revealing the molecular basis of this high-affinity interaction. The IL-2 cytokine adopts a four-helix bundle structure. IL2RA binds to a surface on IL-2 that is distinct from the binding sites for IL2RB and IL2RG. Specifically, the two sushi domains of IL2RA clamp around helix I and the AB loop of IL-2. This binding does not induce significant conformational changes in IL-2 but serves to dramatically increase the local concentration of IL-2 at the cell surface, facilitating its capture by the lower-affinity IL2RB/IL2RG dimer. The "V" shape of the IL2RA sushi domains creates a large, complementary interface that buries a substantial surface area, contributing to the high affinity and slow off-rate of the interaction.

### 2.3 Post-Translational Modifications

IL2RA is heavily glycosylated. The extracellular domain contains multiple N-linked glycosylation sites (e.g., Asn-49, Asn-68, Asn-90, Asn-113, Asn-160, Asn-191). This glycosylation is essential for proper protein folding, stability, and cell-surface expression. The mature protein migrates as a diffuse band of 55 kDa on SDS-PAGE, despite a core protein mass of only ~28 kDa, due to this extensive glycosylation. O-linked glycosylation has also been reported. The glycosylation pattern can influence the receptor's affinity for IL-2 and its susceptibility to proteolytic cleavage.

### 2.4 Interactive 3D Visualization

To explore the three-dimensional structure of the IL2RA protein and its complex with IL-2, use the interactive visualizer below. This tool allows for the manipulation of the protein structure, highlighting key domains, binding sites, and post-translational modifications.

[Interactive 3D Protein Visualizer: Load IL2RA (PDB: true)](/tools/protein-structure-viewer?source=alphafold&accession=P01589)

## 3. Cellular Signaling Pathways & Molecular Function

### 3.1 The IL-2 Signaling Cascade

IL2RA is the ligand-binding subunit of the high-affinity IL-2 receptor. IL-2 signaling is a cornerstone of the immune system, with opposing roles in promoting immune responses and maintaining immune tolerance. The outcome of IL-2 signaling is highly context-dependent, determined by the cell type and the differentiation state of the cell.

The signaling cascade is initiated when IL-2 binds to the high-affinity receptor complex (IL2RA/IL2RB/IL2RG). This binding brings the cytoplasmic domains of IL2RB and IL2RG into close proximity, activating the receptor-associated Janus kinases (JAKs). JAK1 is constitutively associated with IL2RB, while JAK3 is associated with IL2RG. Upon receptor dimerization, these JAKs transphosphorylate each other and then phosphorylate specific tyrosine residues on the cytoplasmic tails of the receptor subunits.

These phosphorylated tyrosines serve as docking sites for Src Homology 2 (SH2) domain-containing signaling proteins. The most critical of these is the Signal Transducer and Activator of Transcription 5 (STAT5). STAT5a and STAT5b bind to the phosphorylated IL2RB chain, are subsequently phosphorylated by JAKs, and then dimerize. The activated STAT5 dimers translocate to the nucleus, where they bind to gamma-interferon activation site (GAS) motifs in the promoters of target genes, driving their transcription. Key STAT5 target genes include *FOXP3*, *MYC*, *BCL2*, and *IL2RA* itself, creating a positive feedback loop that amplifies IL-2 signaling [1].

### 3.2 The PI3K/AKT and MAPK Pathways

In addition to the JAK-STAT pathway, IL-2 signaling activates the Phosphatidylinositol 3-kinase (PI3K)/AKT pathway and the Mitogen-Activated Protein Kinase (MAPK) pathway. The phosphorylated IL2RB chain recruits the adaptor protein Shc, which in turn activates the GRB2-SOS complex, leading to the activation of RAS and the downstream RAF/MEK/ERK cascade. This pathway is critical for IL-2-induced cell proliferation.

Simultaneously, the recruitment of PI3K to the receptor complex leads to the generation of Phosphatidylinositol (3,4,5)-trisphosphate (PIP3), which activates AKT. AKT promotes cell survival and metabolism by phosphorylating targets such as BAD, FOXO transcription factors, and mTOR. The PI3K/AKT pathway is particularly important for the survival and metabolic fitness of Tregs.

### 3.3 Differential Signaling in Tregs vs. Conventional T Cells

The functional dichotomy of IL-2 signaling is a result of the differential expression of IL2RA and downstream signaling components in different T-cell subsets.

- **Regulatory T Cells (Tregs):** Tregs constitutively express high levels of IL2RA. They are critically dependent on IL-2 for their survival, homeostasis, and suppressive function. In Tregs, IL-2 signaling is primarily routed through the JAK-STAT5 pathway, which is essential for maintaining high-level expression of FOXP3, the master transcription factor for Treg identity [1]. The IL-2/STAT5 axis in Tregs drives the expression of anti-apoptotic proteins and metabolic programs that support their suppressive function. The super-enhancer at the IL2RA locus is stabilized by FOXP3, creating a feed-forward loop that ensures robust IL2RA expression and Treg fitness [2].
- **Conventional T Cells (Tconv):** Naive Tconv cells express low levels of IL2RA. Upon TCR activation, IL2RA expression is rapidly induced, and IL-2 signaling promotes clonal expansion and differentiation into effector cells. In these cells, IL-2 signaling strongly activates the PI3K/AKT and MAPK pathways, driving proliferation and the acquisition of effector functions, such as cytokine production (e.g., IFN-γ, TNF-α). However, IL-2 signaling also induces the expression of pro-apoptotic proteins like FAS ligand, which is crucial for the contraction phase of the immune response and the maintenance of peripheral tolerance.

### 3.4 Negative Feedback Regulation

IL-2 signaling is tightly regulated by several negative feedback mechanisms to prevent uncontrolled immune activation.

1.  **Suppressor of Cytokine Signaling (SOCS) Proteins:** SOCS1 and SOCS3 are induced by STAT5 and directly inhibit JAK kinase activity, terminating the signaling cascade.
2.  **Protein Tyrosine Phosphatases:** The SH2 domain-containing protein tyrosine phosphatase 2 (SHP2) can be recruited to the receptor complex and dephosphorylate JAKs and the receptor itself.
3.  **CD25-Mediated Feedback:** Recent studies have revealed a novel, non-canonical role for IL2RA in negative feedback control. In acute lymphoblastic leukemia (ALL), CD25 recruits the protein tyrosine phosphatase PTPN2 (TC-PTP) to the cell membrane, where it dephosphorylates and inactivates STAT5 [2]. This mechanism acts as a "brake" on IL-2 signaling, preventing excessive oncogenic signaling. This function is particularly relevant in cancer, where IL2RA expression can paradoxically be associated with a more favorable prognosis in some contexts due to this negative feedback [2].
4.  **Soluble IL-2Rα (sIL-2Rα):** The proteolytic cleavage of membrane-bound CD25 releases sIL-2Rα, which can bind to IL-2 in the extracellular space, sequestering it and reducing its availability for cell-surface receptors. This acts as a buffer system, modulating the magnitude of IL-2 responses.

### 3.5 Protein-Protein Interaction Networks

The IL2RA protein is part of a complex interactome. Its primary interactions are with IL-2, IL2RB, and IL2RG. However, it also interacts with a variety of other proteins that modulate its function or mediate its non-canonical roles. These include:

- **ADAM17 (TACE):** The metalloprotease responsible for cleaving membrane-bound CD25 to generate sIL-2Rα.
- **PTPN2 (TC-PTP):** A phosphatase that is recruited by CD25 to dephosphorylate STAT5, as described above [2].
- **PRDM1 (Blimp-1):** A transcription factor that directly represses IL2RA transcription in NK cells, providing a mechanism for terminating IL-2-driven expansion [1, 2].
- **FOXP3:** While not a direct protein-protein interaction, FOXP3 is critical for the epigenetic maintenance of the IL2RA super-enhancer in Tregs [2].

## 4. Pathogenic Hotspot Mutations & Clinical Differentials

### 4.1 Germline Mutations Causing Immunodeficiency 41

Biallelic, loss-of-function mutations in IL2RA cause a rare, severe primary immunodeficiency known as Immunodeficiency 41 with lymphoproliferation and autoimmunity (IMD41; OMIM #606367). This condition is characterized by a failure of immune tolerance, leading to multi-organ autoimmunity, chronic lymphoproliferation, and increased susceptibility to infections.

The mutations identified in IMD41 are diverse and include missense, nonsense, frameshift, and splice-site mutations. These mutations typically result in the complete loss of CD25 expression on the cell surface or the production of a non-functional protein. For example, a novel heterozygous mutation was identified in a Chinese girl presenting with lymphoproliferation, autoimmunity, and insulin-dependent diabetes [1]. The clinical phenotype is highly variable, but common features include:

- **Autoimmune manifestations:** Enteropathy, dermatitis, hemolytic anemia, thyroiditis, type 1 diabetes, and hepatitis [1, 2].
- **Lymphoproliferation:** Lymphadenopathy, hepatosplenomegaly.
- **Infections:** Recurrent bacterial and viral infections, including severe CMV and EBV infections.
- **Granulomatous inflammation:** Granulomatous hepatitis has been reported [2].

The diagnosis of IMD41 is confirmed by genetic testing and by the demonstration of absent CD25 expression on T cells via flow cytometry. The definitive treatment is allogeneic hematopoietic stem cell transplantation (HSCT). However, gene-corrected regulatory T cell therapy is emerging as a promising alternative. Preclinical studies have demonstrated that CRISPR-mediated gene correction of IL2RA in patient-derived T cells can restore CD25 expression and Treg suppressive function, offering a potential autologous, non-genotoxic therapeutic approach [1, 2].

### 4.2 Common Polymorphisms and Autoimmune Disease Susceptibility

In stark contrast to the rare, highly penetrant mutations causing IMD41, common single-nucleotide polymorphisms (SNPs) within the IL2RA locus are associated with susceptibility to a wide range of autoimmune diseases, including Type 1 Diabetes (T1D), Multiple Sclerosis (MS), Rheumatoid Arthritis (RA), Alopecia Areata, and Juvenile Idiopathic Arthritis (JIA) [1, 2]. These SNPs are non-coding and are thought to exert their effects by subtly altering IL2RA gene expression, thereby modulating the delicate balance of immune tolerance.

The most extensively studied SNPs include:

- **rs2104286 (A>G):** Located in the first intron. The minor 'A' allele is associated with increased risk for MS and T1D [1, 2]. This variant has been shown to influence IL2RA expression and the production of GM-CSF in human T-helper cells [2]. It also affects DNA methylation and gene expression in CD8+ T cells [1].
- **rs12722489 (C>T):** Also located in the first intron. This variant is associated with MS, RA, and Crohn's disease [2]. It has been shown to determine differential estrogen receptor binding and enhancer properties of the IL2RA intronic region [2].
- **rs11594656 (A>T):** Associated with T1D and intermediate uveitis [1, 2].
- **rs12722495 (C>T):** Associated with intermediate uveitis [2].
- **rs11256593:** Associated with MS [1].

These SNPs often reside within or near the enhancer elements identified in the IL2RA super-enhancer. For instance, the MS and T1D risk alleles are associated with reduced IL2RA expression, particularly in naive T cells and Tregs. This reduction in CD25 levels is thought to impair Treg function and IL-2-mediated feedback control, leading to a breakdown in self-tolerance [1, 2]. The risk variants can disrupt the binding of transcription factors such as STAT5, GABP, and NF-κB, thereby altering enhancer activity and gene expression [1, 2]. A cis-acting regulatory variant has been identified that directly affects IL2RA transcription [1].

The genetic architecture of IL2RA-associated disease risk is complex, with evidence of allelic heterogeneity. Different SNPs within the locus can have independent or synergistic effects on disease susceptibility, and the risk alleles can differ between diseases. For example, the association of IL2RA with MS and T1D is not fully explained by the same set of SNPs, indicating that different causal variants may be at play in different diseases [1, 2].

### 4.3 Somatic Alterations in Cancer

IL2RA expression is frequently dysregulated in cancer. It is a classic marker for several hematological malignancies, including adult T-cell leukemia/lymphoma (ATL), cutaneous T-cell lymphoma (CTCL), and hairy cell leukemia. In these diseases, malignant T cells often express high levels of CD25, which can drive autocrine or paracrine IL-2 signaling loops that promote tumor cell growth and survival.

However, the role of IL2RA in cancer is not always oncogenic. In B-cell acute lymphoblastic leukemia (B-ALL), CD25 expression has been shown to act as a tumor suppressor by recruiting inhibitory phosphatases and mediating negative feedback control of STAT5 signaling [2]. This paradoxical role highlights the context-dependent nature of IL2RA function.

In solid tumors, IL2RA is primarily expressed on tumor-infiltrating lymphocytes (TILs), particularly Tregs. High levels of IL2RA expression in the tumor microenvironment are often associated with an immunosuppressive milieu and poor prognosis. For example, an IL2RA+VSIG4+ tumor-associated macrophage subpopulation has been identified as a key driver of the immunosuppressive microenvironment in anaplastic thyroid cancer [2]. Similarly, IL2RA expression is a prognostic indicator in pancreatic ductal adenocarcinoma, correlating with immune infiltration and patient outcomes [1]. In lung cancer, polymorphisms in IL2RA and IL2RB have been associated with altered risk [2].

### 4.4 Epigenetic Regulation and Disease

Beyond genetic variation, epigenetic modifications at the IL2RA locus contribute to its dysregulation in disease.

- **DNA Methylation:** The IL2RA promoter contains several CpG dinucleotides whose methylation status correlates with gene expression. Hypomethylation of the promoter is associated with active transcription, while hypermethylation is associated with gene silencing. In T1D, altered CpG methylation within the IL2RA promoter has been observed, suggesting an epigenetic component to disease susceptibility [1]. Similarly, DNA methylation analysis within the IL2RA promoter has been studied in youth with autoimmune thyroid disease [2]. In MS, the risk-associated SNP rs2104286 has been linked to altered methylation and gene expression in CD8+ T cells [1].
- **Histone Modifications:** The IL2RA super-enhancer is marked by H3K27ac and H3K4me1, which are hallmarks of active enhancers. The binding of STAT5 and FOXP3 is critical for maintaining these active marks. In Tregs, FOXP3 stabilizes the super-enhancer structure, ensuring sustained IL2RA expression [2]. In disease states, disruption of these epigenetic marks can lead to altered IL2RA expression.

## 5. Host-Pathogen & Viral Interactions

IL2RA is a central node in the immune system, and as such, it is a target for modulation by various pathogens seeking to evade or subvert immune responses.

### 5.1 Viral Interactions

- **Human T-cell Leukemia Virus Type 1 (HTLV-1):** HTLV-1 is the etiological agent of Adult T-cell Leukemia/lymphoma (ATL), an aggressive malignancy of CD4+ T cells. The viral oncoprotein Tax is a potent transactivator of viral and cellular genes. Tax activates the NF-κB pathway, which in turn drives the expression of IL2RA. The resulting high-level expression of CD25 on ATL cells is a hallmark of the disease. The IL2RA promoter is thus a critical downstream target of Tax-mediated transformation. Furthermore, recent research has shown that N6-methyladenosine (m6A) RNA modification controls HTLV-1 Tax and host gene expression, including potentially IL2RA, adding another layer of complexity to the host-virus interaction [1].
- **Epstein-Barr Virus (EBV):** EBV is a herpesvirus that establishes lifelong latency in B cells. EBV infection is associated with hemophagocytic lymphohistiocytosis (HLH), a hyperinflammatory syndrome. Polymorphisms in IL2RA and IL-10 have been investigated for their association with EBV-HLH susceptibility in children [2]. The virus can also infect T cells in some cases, potentially modulating IL2RA expression.
- **Cytomegalovirus (CMV):** CMV is a betaherpesvirus that can cause severe disease in immunocompromised individuals. CMV infection leads to the expansion of virus-specific T cells, which express high levels of CD25. The virus itself does not appear to directly target IL2RA, but the host's IL-2/IL2RA axis is critical for controlling the infection.

### 5.2 Bacterial and Parasitic Interactions

- **Mycobacterium leprae:** Leprosy is a chronic infectious disease caused by *Mycobacterium leprae*. The clinical form of the disease (paucibacillary vs. multibacillary) depends on the host's immune response. Polymorphisms in the TGFB1 and IL2RA genes have been associated with the clinical forms of leprosy in a Brazilian population, suggesting that genetic variation in IL2RA can influence the host's ability to contain the infection [1].
- **Mycobacterium tuberculosis:** Tuberculosis (TB) remains a major global health threat. The host genetic background plays a significant role in determining susceptibility to active TB. Gene expression pattern analysis and eQTL studies have implicated IL2RA in TB susceptibility [2].
- **Leishmania spp.:** Leishmaniasis is a parasitic disease caused by *Leishmania* species. IL-2 signaling is critical for the development of a protective Th1 immune response. Genetic variants in IL2RA that reduce IL-2-dependent responses have been shown to aggravate human cutaneous leishmaniasis [1, 2]. These variants likely impair the ability of T cells to expand and produce IFN-γ, leading to uncontrolled parasite growth.

## 6. Pharmacogenomics, Drug Targets & Small-Molecule Inhibitors

Given its central role in immune regulation, IL2RA is a prime target for therapeutic intervention. Strategies range from monoclonal antibodies that block IL-2 binding to engineered cytokines that selectively expand Tregs.

### 6.1 Monoclonal Antibodies

- **Daclizumab (Zenapax):** A humanized monoclonal antibody that binds to the alpha subunit (CD25) of the IL-2 receptor. It was initially approved for the prevention of acute kidney transplant rejection. Daclizumab was later investigated and approved for the treatment of relapsing-remitting multiple sclerosis (RRMS). However, it was withdrawn from the market worldwide in 2018 due to severe autoimmune adverse events, including fulminant liver failure and immune-mediated encephalitis. The mechanism of action in MS was thought to involve the blockade of IL-2 signaling in activated T cells, but paradoxically, it led to an expansion of "pro-inflammatory" NK cells and a reduction in Tregs, which may have contributed to its toxicity.
- **Basiliximab (Simulect):** A chimeric (mouse/human) monoclonal antibody that also targets CD25. It is used for the prophylaxis of acute organ rejection in de novo renal transplantation. It is typically used as part of a dual or triple immunosuppressive regimen. Basiliximab is generally well-tolerated and has a more favorable safety profile than daclizumab, likely due to its shorter half-life and different binding epitope.
- **Inolimomab:** A rat monoclonal antibody against CD25, which has been used as a second-line treatment for steroid-resistant acute graft-versus-host disease (GVHD).

### 6.2 Engineered Cytokines and Fusion Proteins

- **Aldesleukin (Proleukin):** A recombinant form of human IL-2. High-dose aldesleukin is approved for the treatment of metastatic melanoma and renal cell carcinoma. It works by activating and expanding cytotoxic T cells and NK cells. However, its use is limited by severe dose-limiting toxicities, including vascular leak syndrome. Low-dose IL-2 therapy is being investigated for the treatment of autoimmune diseases, as it preferentially expands Tregs, which have a higher affinity for IL-2 due to their constitutive expression of CD25.
- **IL-2 Mutains (e.g., NKTR-214, bempegaldesleukin):** These are engineered variants of IL-2 designed to preferentially activate either Tregs or effector T cells. For example, NKTR-214 is a PEGylated form of IL-2 that is designed to bias signaling towards the IL2RB/IL2RG dimer, thereby activating effector T cells and NK cells while minimizing Treg expansion. This approach is being evaluated in combination with checkpoint inhibitors for cancer immunotherapy.
- **IL-2/anti-IL-2 Antibody Complexes:** These are pre-formed complexes of IL-2 and a specific anti-IL-2 monoclonal antibody. Depending on the antibody clone used, these complexes can selectively expand either Tregs (e.g., JES6-1) or effector/memory T cells (e.g., S4B6). This approach is a powerful tool for manipulating the IL-2/IL2RA axis in vivo and is being explored for both autoimmune disease and cancer therapy.

### 6.3 Small-Molecule Inhibitors

Direct small-molecule inhibition of IL2RA is challenging due to the protein-protein interaction nature of the IL-2/IL2RA binding interface. However, downstream signaling components, such as JAK kinases, are druggable targets.

- **JAK Inhibitors (JAKinibs):** Tofacitinib, ruxolitinib, and baricitinib are FDA-approved JAK inhibitors that block the signaling pathways downstream of the IL-2 receptor. By inhibiting JAK1/JAK3, these drugs effectively block IL-2-mediated STAT5 phosphorylation and downstream gene expression. They are used for the treatment of rheumatoid arthritis, psoriatic arthritis, ulcerative colitis, and myelofibrosis. Their efficacy is partly due to the suppression of IL-2 signaling in pathogenic T cells.
- **BTP2 (YM-58483):** A pyrazole derivative that inhibits store-operated calcium entry (SOCE). Since calcium flux is essential for NFAT activation and subsequent IL2RA transcription, BTP2 can indirectly suppress IL2RA expression. It has been shown to preserve anti-inflammatory gene expression in human peripheral blood mononuclear cells [2].

### 6.4 Gene Therapy and Cell Therapy

- **CRISPR Gene Correction:** For patients with IMD41, gene therapy approaches are being developed. Non-viral genome targeting using CRISPR-Cas9 has been used to correct IL2RA mutations in primary human T cells [2]. More recently, gene-corrected regulatory T cell therapy has shown promise in preclinical models, restoring Treg function and offering a potential cure for IL2RA deficiency [1].
- **CAR-T Cell Therapy:** Chimeric Antigen Receptor (CAR) T cells targeting CD25 are being explored for the treatment of CD25+ malignancies, such as ATL and CTCL. This approach uses the specificity of an anti-CD25 antibody to redirect T cells to kill tumor cells.

## 7. Bioinformatic Resources & Database Accessions

The following table provides key database accessions and resources for the IL2RA gene and protein.

| **Database** | **Identifier / Link** | **Description** |
| :--- | :--- | :--- |
| **NCBI Gene** | [1](https://www.ncbi.nlm.nih.gov/gene/3569) | Gene-specific information, genomic context, and reference sequences. |
| **Ensembl** | [ENSG00000134460](https://www.ensembl.org/Homo_sapiens/Gene/Summary?db=core;g=ENSG00000134460) | Comprehensive genome annotation, transcripts, and variation data. |
| **UniProt** | [P01589](https://www.uniprot.org/uniprotkb/P01589/entry) | Protein sequence, function, post-translational modifications, and structure. |
| **RCSB PDB** | [2ERJ](https://www.rcsb.org/structure/2ERJ), [2B5I](https://www.rcsb.org/structure/2B5I) | Experimentally determined 3D structures of IL-2/IL-2Rα complexes. |
| **OMIM** | [2](https://www.omim.org/entry/606367) | Mendelian inheritance and disease associations (IMD41). |
| **ClinVar** | [IL2RA](https://www.ncbi.nlm.nih.gov/clinvar/?term=IL2RA%5Bgene%5D) | Curated database of human genetic variants and their clinical significance. |
| **Gene Ontology (GO)** | [GO:0004911](https://www.ebi.ac.uk/QuickGO/term/GO:0004911) (IL-2 receptor activity), [GO:0005886](https://www.ebi.ac.uk/QuickGO/term/GO:0005886) (plasma membrane) | Functional annotations for molecular function, biological process, and cellular component. |
| **STRING** | [P01589](https://string-db.org/network/9606.ENSP00000256891) | Protein-protein interaction networks. |
| **BioGRID** | [IL2RA](https://thebiogrid.org/109063) | Curated protein and genetic interactions. |

## Related Clinical & Scientific Guides

* [TARM1 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/immunology-checkpoints/tarm1-gene-structure-function-pathway)
* [TRAC Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/immunology-checkpoints/trac-gene-structure-function-pathway)
* [CFD Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/immunology-checkpoints/cfd-gene-structure-function-pathway)

## References

[1] Spolski, R., Li, P., Chandra, V., Shin, B., Liu, C., Oh, J., Ren, M., Enomoto, Y., West, E., Christensen, S. M., Wan, E., Ge, M., Lin, J.-X., Vijayanand, P., Rothenberg, E., & Leonard, W. (2022). Distinct super-enhancer elements differentially control Il2ra gene expression in a cell-type specific fashion. *bioRxiv*. [Link](https://www.semanticscholar.org/paper/55e074823c4f4c1fdda942d3249baf3b0de6a9ad)

[2] Li, P., Mitra, S., Spolski, R., Oh, J., Liao, W., Tang, Z., Mo, F., Li, X., West, E., Gromer, D., Lin, J.-